In a recent publication in Cureus, researchers conducted a systematic review to evaluate the cardiovascular (CV) mortality rates between sotagliflozin and dapagliflozin in patients with heart failure (HF).

The authors wrote, “On May 26, 2023, there was a remarkable update in the field of cardiology. On the basis of the phase three results of the effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) and Sotagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes (SCORED) trials, the FDA approved sotagliflozin, making it the first dual sodium-glucose co-transporter 1 and 2 (SGLT 1 and 2) inhibitor authorized for the treatment of heart failure (HF) in both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).”

The authors also noted that sotagliflozin has been FDA-approved to diminish CV mortality, hospitalization from HF, and urgent visits from HF in adults with HF, type 2 diabetes mellitus, chronic kidney disease, and additional CV risk factors.

The authors indicated that as a result of the recent data from the SOLOIST-WHF and SCORED trials followed by the FDA approval of sotagliflozin, they conducted a systematic review to compare the cardiovascular mortality rates between sotagliflozin and dapagliflozin.

The primary outcome was to compare the variances in CV mortality rates in patients treated with sotagliflozin and dapagliflozin, and the secondary outcomes included variances in HF hospitalization and the necessity for urgent admission for HF.

The researchers searched PubMed, MEDLINE, PubMed Central, Google Scholar, Embase, and Cochrane Library to gather relevant clinical data that met their designated inclusion criteria with regard to trials that included sotagliflozin with the trials studying dapagliflozin to provide comprehensive mortality results of both drugs.

Eleven studies met inclusion criteria after a thorough assessment of published literature, and researchers employed the Assessment of Multiple Systematic Reviews tool for systematic reviews and meta-analyses and the Cochrane risk-of-bias assessment tool for randomized, controlled trials. Of the 11 studies, three were systematic reviews and meta-analyses, two were solely meta-analyses, and the remaining six articles were RCTs.

Based on their findings, the authors wrote, “The results showed that the timely initiation of sotagliflozin in HF cases significantly reduces cardiovascular mortality, hospitalizations, and urgent HF visits. Comparative trials with dapagliflozin indicate enhanced mortality reduction associated with greater initial symptom burden.”

The authors also indicated that the use of sotagliflozin resulted in an increase in the count of days patients were alive and not hospitalized, and these benefits provide an added patient-centered measure to assess the impact of the disease burden.

Lastly, the authors noted that the data from this review provides future researchers with valuable information, and there is a need for future large-scale trials with sotagliflozin to recognize and employ this novel agent in the treatment of patients with HF as a therapy that has the potential to reduce mortality rates as well as enhance health-related quality of life in individuals with HF.

The content contained in this article is for informational purposes only. The content is not intended to be a substitute for professional advice. Reliance on any information provided in this article is solely at your own risk.